Tsubasa Takemori1, Yoshimasa Oyama2, Takenori Makino1, Seigo Hidaka1, Takaaki Kitano1. 1. Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Oita University, 1-1 Idaigaoka-Hasamamachi, Yufu City, Oita, 879-5593, Japan. 2. Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Oita University, 1-1 Idaigaoka-Hasamamachi, Yufu City, Oita, 879-5593, Japan. oyama@oita-u.ac.jp.
Abstract
BACKGROUND: Remimazolam is an ultra-short-acting benzodiazepine anesthetic that is antagonized by flumazenil, and it is typically expected to be applied in anesthesia with the purpose of ensuring early postoperative recovery. We report a case of long-term delayed emergence with re-sedation even after three times of flumazenil administration. CASE PRESENTATION: A 71-year-old man was scheduled for a robotic-assisted laparoscopic radical prostatectomy for prostate cancer. We used remimazolam for anesthetic induction and maintenance. The intraoperative bispectral index (BIS) was 30-50. Flumazenil was administered as patient emergence was delayed after surgery; however, re-sedation was observed. This finding persisted till 12 h after surgery, and the patient awakened on postoperative day 2. CONCLUSIONS: Remimazolam is a short-acting anesthetic, but long-term delayed emergence with re-sedation may occur even after flumazenil administration. Anesthesia using remimazolam requires anesthesia management that takes into account the individual differences in sensitivity and metabolism, with BIS as the indicator.
BACKGROUND: Remimazolam is an ultra-short-acting benzodiazepine anesthetic that is antagonized by flumazenil, and it is typically expected to be applied in anesthesia with the purpose of ensuring early postoperative recovery. We report a case of long-term delayed emergence with re-sedation even after three times of flumazenil administration. CASE PRESENTATION: A 71-year-old man was scheduled for a robotic-assisted laparoscopic radical prostatectomy for prostate cancer. We used remimazolam for anesthetic induction and maintenance. The intraoperative bispectral index (BIS) was 30-50. Flumazenil was administered as patient emergence was delayed after surgery; however, re-sedation was observed. This finding persisted till 12 h after surgery, and the patient awakened on postoperative day 2. CONCLUSIONS: Remimazolam is a short-acting anesthetic, but long-term delayed emergence with re-sedation may occur even after flumazenil administration. Anesthesia using remimazolam requires anesthesia management that takes into account the individual differences in sensitivity and metabolism, with BIS as the indicator.
Authors: Laurie J Antonik; D Ronald Goldwater; Gavin J Kilpatrick; Gary S Tilbrook; Keith M Borkett Journal: Anesth Analg Date: 2011-12-20 Impact factor: 5.108
Authors: Gavin J Kilpatrick; Margaret S McIntyre; Richard F Cox; Jeffrey A Stafford; Gregory J Pacofsky; Gwyer G Lovell; Robert P Wiard; Paul L Feldman; Holly Collins; Barbara L Waszczak; Gary S Tilbrook Journal: Anesthesiology Date: 2007-07 Impact factor: 7.892
Authors: Thomas Stöhr; Pieter J Colin; Joachim Ossig; Marija Pesic; Keith Borkett; Peter Winkle; Michel M R F Struys; Frank Schippers Journal: Br J Anaesth Date: 2021-07-08 Impact factor: 9.166
Authors: Shaotong Zhu; Colleen M Noviello; Jinfeng Teng; Richard M Walsh; Jeong Joo Kim; Ryan E Hibbs Journal: Nature Date: 2018-06-27 Impact factor: 49.962